Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Rajabto W., Priantono D., Mulyadi R.
36519576100;57219443427;56403164500;
Pulmonary Embolism in Hospitalized Patient with Coronavirus Disease 2019 (COVID-19)
2021
Acta medica Indonesiana
53
4
493
496
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General HospitalJakarta, Indonesia
Rajabto, W., Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo General HospitalJakarta, Indonesia; Priantono, D.; Mulyadi, R.
Coronavirus disease 2019 (COVID-19) has been a global pandemic for over a year. Meanwhile, thrombosis occurs in up to one-third of hospitalized patients with the disease, while pulmonary embolism has been reported to be the most dangerous thrombosis which greatly increases mortality in COVID-19.Hospitalized patients with COVID-19 are at high risk of thromboembolic complications such as deep vein thrombosis and pulmonary embolism. The hypercoagulable state caused by COVID-19 leads to activation of coagulation cascade, meanwhile, CT pulmonary angiography is used to diagnose or exclude pulmonary embolism. Furthermore, ground-glass opacities are also evaluated using this modality. Low molecular weight heparin is the anticoagulant of choice due to simplicity in administration and low risk of drug-drug interactions.Pulmonary embolism occurs in COVID-19 patients without DVT. Based on the results, parenteral anticoagulant followed by DOAC is the mainstay of treatment in COVID-19 coagulopathy.
COVID-19; pulmonary embolism; thrombosis
anticoagulant agent; complication; diagnostic imaging; human; lung embolism; vein thrombosis; virology; Anticoagulants; COVID-19; Humans; Pulmonary Embolism; SARS-CoV-2; Venous Thrombosis
NLM (Medline)
01259326
35027499
Article
Q3
321
14162